CAMBRIDGE, Mass.--(BUSINESS WIRE)--Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic products, today announced the availability of its first Laboratory ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta Biosciences, a precision oncology company ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Shares of Tempus AI rose after the medical technology company said it was expanding the commercial availability of whole-genome sequencing assay technology to detect and analyze cancer cells in ...
Brian McKernan joins as CEO to further advance Predicta’s clinical impact, including its non-invasive diagnostic for Multiple Myeloma “It’s an honor to join Predicta and our strong team of leading ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta Biosciences, a precision oncology company developing novel diagnostic ...
Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring Tempus AI, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results